【摘要】

【摘要】目的:探讨卡马西平联合丙戊酸钠治疗小儿早期癫痫伴抑郁焦虑临床疗效及其安全性。
方法：将已确诊为小儿早期癫痫伴抑郁焦虑的80例患者采用随机对照
方法分为联合治疗组和单药治疗组，每个小组各40例。联合用药组给予卡马西平+丙戊酸钠治疗，单独用药组给予丙戊酸钠治疗，疗程均为12周。治疗12周后采用复查脑电图，并依据发作频次判断小儿早期癫痫疗效，匹兹堡睡眠质量指数量表（PSQI）评定抑郁焦虑疗效，不良应量表（TESS）评价药品不良反应（ADR）。
结果：治疗12周后，联用组有效率（92.5％）显著高于单用组（85.0％）（P＜0.05）；联用组治疗后小儿早期癫痫康复率显著（有明显疗效37人，有效率92.5％）高于单药治疗组（有明显疗效34人，有效率85.0％），联合用药组PSQI评分显著低于单用组（P＜0.01）；治疗后2组ADR发生率比较，差异无统计学意义（P＞0.05）。
结论：卡马西平联合丙戊酸钠治疗小儿早期癫痫伴抑郁焦虑比较单独用药疗效显著，且不增加ADR的发生率。

【Abstract】

【Abstract】 Objective: Discuss carbamazepine combined with sodium valproate in treatment of early epilepsy in children with anxiety and depression clinical efficacy and safety.
Methods: 80 cases of early childhood epilepsy with depression and anxiety were randomly divided into combined treatment group and single drug treatment group, each group had 40 cases. Combined medication group were given carbamazepine and valproate treatment, single drug group given sodium valproate treatment, treatment for 12 weeks. After 12 weeks of treatment with countercheck electroencephalogram, and according to the seizure frequency judgment early children epilepsy, Pittsburgh sleep quality index (PSQI scale (PSQI) assessment of depression and anxiety efficacy and adverse reactions scale (TESS) were used to evaluate the adverse drug reaction (ADR).
Results: after 12 weeks of treatment, group have efficiency (92.5%) was significantly higher than that of single group (85%) (P < 0.05); combined treatment group after epilepsy in children with early rehabilitation rate significantly (37 people have obvious curative effect, with efficiency of 92.5%) higher than that of the single drug treatment group (has obvious curative effect of 34 people, 85.0% efficiency), combination group PSQI score was significantly lower than that of single group (P < 0.01); treatment group 2 ADR incidence rate, the difference was not statistically significant (P > 0.05).
Conclusion  : carbamazepine combined with sodium valproate in treatment of early epilepsy in children with depression and anxiety between single drug efficacy significantly, and does not increase the ADR incidence.